The nurse gets hand-off report on four patients. Which patient would the nurse assess first?

Choice A reason: Increased serum calcium is not typically associated with advanced liver disease. Hypercalcemia (increased serum calcium) may be seen in conditions like hyperparathyroidism, certain cancers, or excessive vitamin D intake, but it is not a common finding in liver disease.

Choice B reason: Decreased serum ammonia is also not associated with advanced liver disease. In fact, patients with liver disease often have increased serum ammonia levels due to the liver's inability to effectively detoxify ammonia into urea. Elevated ammonia can lead to hepatic encephalopathy, a serious complication of liver disease.

Choice C reason: Increased ALT and AST are common laboratory findings in advanced liver disease. These liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are released into the bloodstream when liver cells are damaged or inflamed. Elevated levels indicate liver injury or dysfunction and are often used to assess the extent of liver disease.

Choice D reason: Decreased albumin is a typical finding in advanced liver disease. Albumin is a protein produced by the liver, and its levels drop when the liver is no longer able to synthesize it effectively. Low albumin levels can lead to edema and ascites due to decreased oncotic pressure in the blood vessels.

Choice E reason: Elevated bilirubin is expected in advanced liver disease. Bilirubin is a byproduct of red blood cell breakdown that is normally processed and excreted by the liver. When liver function is impaired, bilirubin accumulates in the blood, leading to jaundice, characterized by yellowing of the skin and eyes.

Choice F reason: Elevated prothrombin time (PT) is a common finding in advanced liver disease. The liver produces clotting factors necessary for blood coagulation, and when it is damaged, these factors are not produced adequately, leading to prolonged PT. This indicates a higher risk of bleeding and impaired clotting function.

Choice A reason: An increased heart rate is not an expected therapeutic response to adenosine. Adenosine is used to slow the heart rate by temporarily blocking the electrical conduction through the atrioventricular (AV) node. This action is crucial in managing supraventricular tachycardia (SVT), as it can help restore a normal heart rhythm. An increased heart rate would suggest that the medication is not working as intended, and the underlying tachycardia may persist or worsen.

Choice B reason: A short period of asystole is the correct and expected therapeutic response when administering adenosine. Adenosine works by briefly stopping the heart's electrical activity, leading to a brief asystole (lack of heartbeat). This allows the heart's natural pacemaker to reset and potentially restore a normal rhythm. Although this can be alarming, it is a known and anticipated effect of the drug, and it typically resolves quickly as the heart resumes normal activity.

Choice C reason: Hypertension is not an expected response to adenosine. Adenosine generally causes vasodilation, which can lower blood pressure. The primary focus of adenosine in the context of SVT is on its cardiac effects rather than influencing blood pressure significantly. If hypertension occurs, it may be unrelated to the administration of adenosine and could indicate another underlying issue that needs to be addressed.

Choice D reason: Decreased intraocular pressure is not a relevant or expected response to adenosine administration in the context of managing SVT. Adenosine's primary effect is on the heart's electrical conduction system, and it does not significantly impact intraocular pressure. The focus should remain on observing the cardiac responses to ensure the medication is effectively managing the SVT.